AngioDynamics Initiates RECOVER-AV Clinical Trial Of AlphaVac F18⁸⁵ System In Pulmonary Embolism And Long-Term Functional Outcomes
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics has initiated the RECOVER-AV clinical trial to evaluate the AlphaVac F18⁸⁵ system for treating pulmonary embolism and assessing long-term functional outcomes.
September 19, 2024 | 8:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AngioDynamics has launched the RECOVER-AV clinical trial to test the AlphaVac F18⁸⁵ system for pulmonary embolism treatment, which could lead to advancements in their product offerings and potentially impact their market position.
The initiation of the RECOVER-AV trial by AngioDynamics is a significant step in evaluating the AlphaVac F18⁸⁵ system for pulmonary embolism. Successful trials could enhance their product offerings and market position, likely leading to a positive short-term impact on their stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90